Authors
Latest:
Strategic Commercialization of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle ValueThe regulatory environment has become increasingly supportive of multi-indication development.
Latest:
Is Community the Next Frontier for Cell and Gene Therapy?Both community and academic delivery models play essential and complementary roles in expanding CGT access.
Latest:
Social Determinants of Health Data Evolution: Improve Access, Adherence and Achieve More Equitable OutcomesWebinar Date/Time: Tue, May 16, 2023 2:00 PM EDT
Latest:
A Pricing Revolution: The State OffensiveThe second of two articles summarizing the broad range of government efforts to control drug pricing focuses on state government efforts.
Latest:
Real-World Evidence Is Becoming a Pivotal Component in Chinese HealthcareIts use enables key processes such as early access, regulatory approval, and reimbursement listing.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Commercial Models for the Changing Life Sciences MarketLife sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Latest:
Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for ExecutivesAn examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.
Latest:
Copay Adjustment Chess Match: What Will Payers Do Next?As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
Latest:
Digital Engagement is Only as Good as the First-Party Data It ProvidesFirst-party insights bridge marketing and sales to deliver better HCP experiences.
Latest:
Precision Medicine: Investments and Outcomes ExpectedPrecision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.
Latest:
AI’s Promise in Delivering on Patient-CentricityHow pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.
Latest:
Redefining Care through Patient PartnershipAstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.
Latest:
How a “Push and Pull” Approach Can Maximize Innovation Value through HTAsHow can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Latest:
Modular Approaches are Opening the Portal to Better HCP EngagementPortals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.
Latest:
Don’t Fall for the Call of Placebo-Controlled Vaccine TrialsThe idea of denying people proven medicines in the name of research has a dark legacy in this country.
Latest:
Succession Attack Plan: Get Strategic with Your Critical RolesOutlining four considerations for biopharma companies in ensuring that their approach to replacing and filling key leadership positions is more truly aligned with future goals in business delivery and risk management.
Latest:
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased EngagementThe benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Latest:
Why Culture, Ethics, and Compliance Are More Important Than Ever Post-COVIDIf the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.
Latest:
FDA’s Guidance on Using RWD in Evidence Generation Is a Big Step ForwardPractices to ensure accuracy in selected datasets.
Latest:
Addressing 4 Common Roadblocks When Using RWD in Regulatory SubmissionsScott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.
Latest:
Value Creation Through Portfolio-Based Corporate StrategyLooking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
Latest:
Breaking OrbitHow pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Latest:
Patient Services Are Simplifying the Healthcare Consumer ExperienceGrowing business segment of life sciences industry improves patient access.
Latest:
How Can Pharma Companies Join the Digital Therapeutics Revolution?More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
It’s Time to Get Creative Hiring in a Post-Brexit European Life Sciences MarketBrexit and the pandemic continue to complicate flow of international talent.
